We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

60 hedge funds and large institutions have $60.8M invested in Theriva Biologics in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

2% less funds holding

Funds holding: 61 → 60 (-1)

5% less capital invested

Capital invested by funds: $64.2M → $60.8M (-$3.39M)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
1.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
17
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$150K
2
State Street
State Street
Massachusetts
+$120K
3
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
+$59.9K
4
Wells Fargo
Wells Fargo
California
+$59.9K
5
Fisher Asset Management
Fisher Asset Management
Washington
+$44.9K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$224K
2
William Blair & Company
William Blair & Company
Illinois
-$180K
3
Millennium Management
Millennium Management
New York
-$92K
4
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$74.8K
5
M&T Bank
M&T Bank
New York
-$66K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$22.8M – – –
KCM
2
Knoll Capital Management
Florida
$6.61M – – –
MP
3
MSD Partners
New York
$5.36M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.77M +$15K +1 +0.3%
BFA
5
BlackRock Fund Advisors
California
$3.53M +$150K +10 +4%
William Blair & Company
6
William Blair & Company
Illinois
$3.44M -$180K -12 -5%
BIT
7
BlackRock Institutional Trust
California
$3.08M +$29.9K +2 +1%
State Street
8
State Street
Massachusetts
$1.64M +$120K +8 +8%
Northern Trust
9
Northern Trust
Illinois
$1.44M +$15K +1 +1%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$850K +$15K +1 +2%
BCM
11
Bridgeway Capital Management
Texas
$769K -$224K -15 -23%
Norges Bank
12
Norges Bank
Norway
$767K – – –
EDRH
13
Edmond de Rothschild Holding
Switzerland
$499K +$15K +1 +3%
EDRS
14
Edmond de Rothschild (Suisse)
Switzerland
$499K +$15K +1 +3%
BIM
15
BlackRock Investment Management
Delaware
$484K – – –
Bank of New York Mellon
16
Bank of New York Mellon
New York
$429K -$59.9K -4 -12%
IA
17
IFP Advisors
Florida
$282K – – –
California State Teachers Retirement System (CalSTRS)
18
California State Teachers Retirement System (CalSTRS)
California
$276K – – –
UBS Group
19
UBS Group
Switzerland
$243K – – –
FSA
20
Franklin Street Advisors
North Carolina
$217K – – –
Morgan Stanley
21
Morgan Stanley
New York
$215K +$15K +1 +8%
TA
22
Teachers Advisors
New York
$207K – – –
Charles Schwab
23
Charles Schwab
California
$204K – – –
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$173K – – –
BA
25
Bard Associates
Illinois
$160K -$15K -1 -8%
1
2 3

TOVX Hedge Fund Activity: Q3 2016 in Review

60 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2016, worth a combined $60.8M — down 5.3% from $64.2M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TOVX and 6 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 17 added.

The largest buyer was BlackRock Fund Advisors, adding an estimated $150K. The largest seller was Bridgeway Capital Management, cutting an estimated $224K.

  • 60 institutional investors held Theriva Biologics (TOVX) as of Q3 2016, down from 61 in Q2 2016.
  • Funds reported $60.8M of Theriva Biologics stock for Q3 2016, down 5.3% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q3 2016 and 7 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $150K added.
  • The largest Theriva Biologics seller in Q3 2016 was Bridgeway Capital Management, an estimated $224K sold.

Based on aggregated 13F filings for Q3 2016.